top stories

A press of­fi­cer at An­tho­ny Fau­ci’s NI­AID was un­masked as a hard-right Covid troll. He just re­tired to­day

7 hours ago
Coronavirus

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

Yesterday
Pharma

Rocked by cus­toms in­ves­ti­ga­tion, Leg­end's CFO takes over as CEO Frank Zhang placed un­der house ar­rest

14 hours ago
People
China

Latest

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists

6 hours ago
Coronavirus

#ES­MO20: Bris­tol My­ers marks Op­di­vo's sec­ond ad­ju­vant win — eye­ing a stan­dard of care gap

10 hours ago
R&D
Pharma

#ES­MO20: Push­ing in­to front­line, Mer­ck and Bris­tol My­ers duke it out with new slate of GI can­cer da­ta

11 hours ago
R&D
Pharma

Covid-19 roundup: Trump sug­gests Pfiz­er vac­cine could be first ap­proved; VBI Vac­cines inks de­vel­op­ment deal with ...

13 hours ago
Coronavirus
see latest stream
People

UP­DAT­ED: A mi­cro-cap with a po­ten­tial­ly promis­ing coro­n­avirus drug en­lists mask-skep­tic con­gress­man for DSMB

3 days ago

A long­time Cy­tomX ex­ec re-emerges at Syn­thekine, an $82M Stan­ford spin­out

4 days ago

Sean Bo­hen's break from bio­phar­ma is over. The ex-As­traZeneca CMO has re­tired his Big Phar­ma jer­sey and is now — ...

4 days ago
Startups

La­va breaks pro­longed si­lence with an $83M Se­ries C and two I/O pro­grams set for the clin­ic

4 days ago

Ver­sant teams up with Stan­ford gene edit­ing ex­perts on a $45M next-gen play — mar­ry­ing CRISPR and AAV to fix sick­le ...

5 days ago

Arie Bellde­grun and David Chang god­fa­ther the $110M launch of a new cell ther­a­py play­er. And this one is al­so ...

Last week
Deals

UP­DAT­ED: Two wild weeks for Grail end in $8B Il­lu­mi­na buy­out

16 hours ago

Roche vaults to the front of the NL­RP3 clin­i­cal race, pay­ing $448M up­front to bag In­fla­zome

17 hours ago

Roche looks to ge­net­ic mod­i­fiers for new drug tar­gets, team­ing up with Dutch biotech in $375M deal

18 hours ago
IPOs

Three more biotechs look to jump on­to Nas­daq amid IPO boom, in­clud­ing Nor­bert Bischof­berg­er's Kro­nos

13 hours ago

Seat­tle-based Athi­ra, aim­ing for tough Alzheimer's and Parkin­son's tar­gets, rais­es $204M for IPO

3 days ago

One month af­ter $115M megaround, mus­cle dis­ease-fo­cused Dyne goes pub­lic with $233M IPO

4 days ago

Premium storiesSee all

Here's a look at every­thing Mer­ck­'s BD group has done in the past 12 years, il­lus­trat­ing why the Seat­tle Ge­net­ics ...

Last week
Deals
R&D

Scoop: Gilead’s CAR-T play­er Kite waves good­bye to re­search chief Pe­ter Em­tage as an­oth­er top ex­ec hits the ex­it

Last week
People
Cell/Gene Tx

Brent Saun­ders piv­ots from Al­ler­gan sale to a $460M SPAC, mak­ing him an overnight play­er in one of the hottest ...

Last week
Deals

Long­time biotech vet An­drew Hirsch is tak­ing the top job at C4 — and he clear­ly has some big plans

Last week
People
R&D

Don't missSee all

UP­DAT­ED: #ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

Yesterday
R&D

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

Yesterday
R&D

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave ...

Yesterday
R&D

#ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

2 days ago
Deals
R&D

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

5 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

8 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

10 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

11 months ago

Peer review See all

Sep
18

Vedan­ta Bio­sciences taps Big Phar­ma vet Jef­frey Sil­ber as CMO; Robert Doe­bele leaves be­hind teach­ing post at Col­orado ...

Sep
11

GSK and J&J alum Vi­jay Red­dy to take con­trol of R&D at Tmu­ni­ty; An­drew Hirsch ex­its Agios for CEO job at C4 ...

Sep
4

Scott Ed­mond­son leaves As­traZeneca, starts new chap­ter at Nim­bus; With IPO filed, Taysha pulls to­geth­er an ...

Aug
28

Michael Var­ney comes out of brief Genen­tech 're­tire­men­t' for R&D gig at Eras­ca; Vivek Ra­maswamy's Im­muno­vant re­cruits ...

Aug
21

MD An­der­son­'s Patrick Hwu to helm Mof­fitt Can­cer Cen­ter; Af­ter Rock­well Med­ical ouster, Robert Chioi­ni gets an­oth­er ...

R&D channel feed

Yesterday

#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mu­tant non-small cell lung can­cer has turned up some promis­ing — al­though de­cid­ed­ly ear­ly — re­sults, fu­el­ing the idea that there’s yet room to one up ...

READ MORE

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for ...

2 days ago

#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve ...

3 days ago
latest in R&D

#ES­MO20: Seat­tle Ge­net­ics eyes 4th ap­proval with new da­ta in a crowd­ed field

13 hours ago

Im­mune Reg­u­la­tion, tak­ing two clin­i­cal pro­grams to 're­set' the im­mune sys­tem, nets $53M+ Se­ries B

13 hours ago
Venture

#ES­MO20: 'As good as any PD-1 out there': Re­gen­eron flash­es PD-(L)1 lung can­cer da­ta to ri­val Mer­ck

15 hours ago

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

Yesterday
Pharma

#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can they win over skep­tics?

2 days ago
Pharma
see latest stories

Pharma channel feed

2 days ago

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in Au­gust, as ne­go­ti­a­tions on a pric­ing deal with Pres­i­dent Trump reached a boil­ing point, PhRMA pres­i­dent Stephen Ubl sent an email up­date to the 34 bio­phar­ma chiefs that sit on his ...

READ MORE

Seat­tle Ge­net­ic­s' Astel­las-part­nered ADC nails con­fir­ma­to­ry PhI­II in urothe­lial can­cer

3 days ago
R&D

A month af­ter los­ing its lead pro­gram, Uni­ty Biotech­nol­o­gy cuts 30% of staff in re­struc­tur­ing

6 days ago
R&D
latest in Pharma

Trump ups the stakes with 'grand­dad­dy of them al­l' drug pric­ing ex­ec­u­tive or­der. But he could be run­ning out of time

Last week

Gilead CEO Dan O'­Day's $21B M&A deal to buy Im­munomedics gets some harsh re­views

Last week
Deals

A year out from FDA ap­proval, Ver­tex looks to ex­pand top-sell­ing CF drug to pe­di­atrics

Last week

Phar­ma's bat­tered rep gets a mod­est facelift in the lat­est in­dus­try rat­ings from Gallup — but it's still look­ing pret­ty bad

Last week
Bioregnum
Coronavirus

Roche nabs an FDA OK for Gavre­to, trig­ger­ing a heavy­weight bout with ri­vals at Eli Lil­ly

Last week
R&D
Regulatory
see latest stories

Coronavirus channel feed

3 days ago

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col 'short­ly'

Yes­ter­day, af­ter sus­tained pub­lic pres­sure as Mod­er­na re­leased its Phase III Covid-19 tri­al blue­print, Pfiz­er re­leased its own full tri­al de­sign for their vac­cine tri­als. The move was ...

READ MORE

Covid-19 roundup: Amid calls for trans­paren­cy, Mod­er­na re­leas­es full PhI­II pro­to­col; As­traZeneca tri­al halt thought ...

4 days ago

As­traZeneca pub­lish­es Covid-19 vac­cine PhI­II pro­to­cols in lock­step with Mod­er­na and Pfiz­er. How are they dif­fer­ent?

16 hours ago
latest in Coronavirus

Covid-19 roundup: AlloVir snags IND ap­proval for po­ten­tial T cell ther­a­py; Sanofi and GSK strike 300 mil­lion-dose deal with the EU 

3 days ago

Roche says a sec­ond tri­al of Actem­ra re­vives hopes for IL-6. What now?

3 days ago

An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

5 days ago
R&D

Covid-19 roundup: Warp Speed re­leas­es vac­cine dis­tri­b­u­tion plans, but leaves key ques­tions unan­swered

5 days ago

NIH ‘very con­cerned’ about se­ri­ous side ef­fect in As­traZeneca's PhI­II Covid-19 tri­al

6 days ago
Regulatory
see latest stories